Jason B. Daly - 03 Mar 2026 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role
EVP, Chief Legal Officer
Signature
/s/ Denis Butkovic, Attorney-in-Fact
Issuer symbol
AMRX
Transactions as of
03 Mar 2026
Net transactions value
$0
Form type
4
Filing time
05 Mar 2026, 16:32:25 UTC
Previous filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Daly Jason B. EVP, Chief Legal Officer C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER /s/ Denis Butkovic, Attorney-in-Fact 05 Mar 2026 0001906486

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMRX Class A Common Stock Options Exercise +22,645 +214% 33,251 03 Mar 2026 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -10,147 -31% $13.31* 23,104 03 Mar 2026 Direct F3
transaction AMRX Class A Common Stock Options Exercise +38,226 +165% 61,330 03 Mar 2026 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -16,598 -27% $13.31* 44,732 03 Mar 2026 Direct F3
transaction AMRX Class A Common Stock Options Exercise +24,258 +54% 68,990 03 Mar 2026 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -10,533 -15% $13.31* 58,457 03 Mar 2026 Direct F3
transaction AMRX Class A Common Stock Options Exercise +305,810 +523% 364,267 03 Mar 2026 Direct F4
transaction AMRX Class A Common Stock Tax liability -132,783 -36% $13.31* 231,484 03 Mar 2026 Direct F5
transaction AMRX Class A Common Stock Options Exercise +35,880 +15% 267,364 04 Mar 2026 Direct F1, F2
transaction AMRX Class A Common Stock Tax liability -15,580 -5.8% $13.30* 251,784 04 Mar 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMRX Restricted Stock Units Options Exercise -22,645 -100% $0.000000* 0 03 Mar 2026 Class A Common Stock 22,645 Direct F2, F6
transaction AMRX Restricted Stock Units Options Exercise -38,226 -50% $0.000000* 38,227 03 Mar 2026 Class A Common Stock 38,226 Direct F2, F7
transaction AMRX Restricted Stock Units Options Exercise -24,258 -25% $0.000000* 72,774 03 Mar 2026 Class A Common Stock 24,258 Direct F2, F8
transaction AMRX Performance-Based Restricted Stock Units Options Exercise -305,810 -100% $0.000000* 0 03 Mar 2026 Class A Common Stock 305,810 Direct F4
transaction AMRX Restricted Stock Units Options Exercise -35,880 -33% $0.000000* 71,760 04 Mar 2026 Class A Common Stock 35,880 Direct F2, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3 Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.
F5 Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.
F6 On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F7 On March 3, 2023, the reporting person was granted 152,905 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F8 On March 3, 2025, the reporting person was granted 97,032 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F9 On March 4, 2024, the reporting person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.